Taken together, targeting the cell intrinsic and extrinsic mechanisms of the CTLA-4 pathway with neutralizing antibodies can be considered as a requisite approach to enable other therapeutic strategies aimed to promote or restore tumor-specific T cell immune responses in patients. The gene discussed is CTLA4; the disease is neoplasm.